A Discussion With Experts on the Evolving Therapeutic Landscape in T-Cell Lymphomas: Focus on EZH1/2 Inhibitors

Get up to date on the optimal use of EZH1/2 inhibitors in PTCL with this expert-authored commentary plus downloadable slides and on-demand webcast from a live CCO symposium at ASCO 2022.

Share

Program Content

Activities

PTCL Current Options
PTCL: Current Options and Clinical Outcomes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2022

Expires: June 01, 2023

Anti-EZH1/2 Mechanisms
Mechanisms of Action of EZH1 and EZH2 and Anti-EZH1 and EZH2 Therapies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2022

Expires: June 01, 2023

Anti-EZH1/2 Evidence
Clinical Trial Evidence of the Use of Anti-EZH1/2 Therapies in PTCL and Managing Adverse Events
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2022

Expires: June 02, 2023

No activities added yet

Activities

EZH1/2 Inhibitors in PTCL
Rationale and Evidence for EZH1/2 Inhibitors in PTCL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 08, 2022

Expires: August 07, 2023

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.